Investors at the Cell & Gene Meeting on the Mesa expressed concern, though it may be a while before China can become a ...

Having failed a Phase II study for Parkinson’s monotherapy with its first-in-class GPR6 inhibitor, Cerevance will discuss the Phase III data showing benefit with solengepras as an adjunctive therapy ...

Elixir Medical has won Japanese approval for its DynamX coronary bioadaptor. A launch is planned for mid-2027, while US ...

Ashwagandha tops consumer search interest across the US and five European markets, according to HBW Insight's Google Trends ...

Malta-based B2B company Adalvo has announced plans to establish a new dedicated GLP-1 business unit focused on advancing ...

The South San Francisco company is developing therapies that target extracellular proteins, and its lead candidate is a food ...

Vertex Pharmaceuticals’ CDIO Agam Upadhyay outlines the firm’s three-pronged AI approach, the value realization framework keeping every deployment accountable and the CEO's seemingly impossible ask ...

European medical device market growth slowed to 1.8% in 2025 from 6.0%, and the number of medtech companies fell for the first time in the report’s history, according to MedTech Europe’s 2026 Facts & ...

Warnings mark a first for FDA about OTC topicals rendered unapproved due to labeling for STI treatment and latest action to ...

The long-acting injectable was superior to daily oral therapy at viral suppression in treatment-experienced patients who had ...

HHS' attorney said professional organizations cannot challenge the ACIP member appointments because no final agency action ...

Novo will not submit its Ozempic/Wegovy/Rybelsus franchise and AstraZeneca refused to enter its Calquence into the 340B ...